Sight Sciences, Inc.
As of Oct 22, 2026, Sight Sciences is in Stage 2, the uptrend phase, now in week 10 (since Aug 18, 2026). It closed at $9.09, 2.9% below its 52-week high and above its 200-day average, which is rising.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is SGHT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SGHT among Medical Devices10th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …10 | SGHT | Stage 2 · wk 10 | 92 | +6.9% |
Sight Sciences: quick answers
What stage is Sight Sciences in?
As of Oct 22, 2026, Sight Sciences (SGHT) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 18, 2026 and is in week 10. What the four stages mean
Is Sight Sciences in an uptrend?
Yes. Sight Sciences is in a Stage 2 uptrend. It trades 53.4% above its 200-day average, which is rising.
How far is Sight Sciences from its 52-week high?
Sight Sciences closed at $9.09 on Oct 22, 2026, 2.9% below its 52-week high of $9.36. Its 52-week low is $3.45.
How has Sight Sciences performed over the past year?
As of Oct 22, 2026, Sight Sciences is up 76.2% over the past year and up 21.5% so far in 2026.
Which sector and industry is Sight Sciences in?
Sight Sciences is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.